|6 Months Ended|
Jun. 30, 2022
|Stockholders' Equity Note [Abstract]|
|Stockholders' Equity||Stockholders' Equity
The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share. At June 30, 2022 and December 31, 2021, there were 22,253,232 shares and 21,303,500 shares of common stock outstanding, respectively.
The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.0001 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. As of June 30, 2022 and December 31, 2021, there were 2,120,000 shares of preferred stock outstanding.
Warrants and Options
As of June 30, 2022, the Company had the following warrants and options outstanding: 15,063,800 warrants outstanding, each exercisable for one share of common stock at an exercise price of $11.50 including 11,468,800 in public warrants, 3,595,000 in private placement warrants, 75,000 unit purchase option units that are exercisable for one share of common stock at an exercise price of $10.00 and warrants exercisable for one share of common stock at an exercise price of $11.50. The public warrants expire in December 2025.
The Company has certain warrants which include provisions that affect the settlement amount. Such variables are outside of those used to determine the fair value of a fixed-for-fixed instrument, and as such, the warrants are accounted for as liabilities in accordance with ASC 815-40, Derivatives and Hedging, with changes in fair value included in the condensed consolidated statements of operations.
The warrant liability was $1.4 million and $2.7 million at June 30, 2022 and December 31, 2021, respectively. The gain on change in value of warrant liability for the three and six months ended June 30, 2022 was $1.9 million and $1.3 million, and is recognized in the accompanying condensed consolidated statement of operations. The gain on change in value of warrant liability for the three and six months ended June 30, 2021 was $12.6 million, and $7.7 million, and is recognized in the accompanying condensed consolidated statement of operations.
The following is an analysis of changes in the warrant liability for the six months ended June 30, 2022:
The fair value of the warrants are determined using the publicly-traded price of our common stock on the valuation dates of $3.23 on June 30, 2022 and $5.67 on December 31, 2021. See Note 11. Fair Value Measurements.
The Company has the ability to grant stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and performance compensation awards to current or prospective employees, directors, officers, consultants or advisors under the Company’s 2020 Omnibus Equity Incentive Plan (the “Plan”).
On January 3, 2022, the Company filed a Registration Statement with the SEC to register 1,065,175 additional shares of common stock, $0.0001 par value per share, of the Company under the Plan, pursuant to the “evergreen” provision of the Plan providing for an automatic increase in the number of shares reserved for issuance under the Plan.
As of June 30, 2022 and December 31, 2021, there were approximately 406,000 and 126,000 shares of common stock available for future grants under the Plan, respectively.
Restricted Stock Unit Awards
The following table summarizes activity of restricted stock units during the six months ended June 30, 2022:
Share-based compensation recognized during three and six months ended June 30, 2022 was approximately $0.9 million and $8.3 million, inclusive of stock grants of $3.9 million. Share-based compensation recognized during the three and six months ended June 30, 2021 was $2.6 million and $3.1 million. As of June 30, 2022, there was approximately $13.9 million of total unrecognized compensation cost related to unvested restricted stock units or performance-based restricted stock unit awards to be recognized over a weighted average period of 2.9 years.
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef